Cytokinetics analyst coverage
WebApr 2, 2024 · Financials. In 2024, Cytokinetics reported revenues of $2.0 million for Q4 and $94.6 million for the full year, compared to $55.6 million and $70.4 million in the same periods of 2024. This ... WebAnalyst Estimates Options Snapshot Stock Price Targets Yearly Numbers Estimates CYTK will report 2024 earnings on 02/23/2024 EPS Estimate 2024 2024 2024 2024 -10 -5 0 …
Cytokinetics analyst coverage
Did you know?
WebMar 1, 2024 · SOUTH SAN FRANCISCO, Calif., March 01, 2024(GLOBE NEWSWIRE) -- Cytokinetics, Incorporated(Nasdaq: CYTK) reported financial results for the fourth … WebFintel reports that on April 13, 2024, Baird initiated coverage of Pliant Therapeutics (NASDAQ:PLRX) with a Outperform recommendation. Analyst Price Forecast Suggests 80.40% Upside As of April 6 ...
WebOur Corporate Responsibility Framework. Keep Patients at the Center of our Work. Continue to embed patient centricity across all stages of our business. Maintain strong … WebJan 7, 2024 · Royalty Pharma Extends Capital to Cytokinetics to Support the Commercial Launch of Omecamtiv Mecarbil and the Further Development of Aficamten; Royalty Pharma Purchases Royalties on Future Sales of Aficamten; Cytokinetics to Host Conference Call and Webcast Today at 8:30 a.m. ET; NEW YORK, NY and SOUTH SAN FRANCISCO, …
WebMar 7, 2024 · Cytokinetics (CYTK) Analysts Prediction, Stock Forecast & Price Targets - Simply Wall St View Valuation Cytokinetics Future Growth Future criteria checks 0/6 Cytokinetics, Incorporated's earnings is forecasted to decline at 23.5% and its revenue is expected to decline at 46.6%. WebJan 9, 2024 · By contrast, our data suggests that other companies (with analyst coverage) in the industry are forecast to see their revenue grow 14% per year. ... We have analyst estimates for Cytokinetics ...
WebApr 9, 2024 · Truist Financial initiated coverage on shares of Cytokinetics in a research note on Tuesday, December 20th. They issued a “buy” rating and a $60.00 target price for the company. Bank of America...
WebJul 19, 2024 · The webcast can be accessed through the Investors & Media section of the Cytokinetics website at www.cytokinetics.com. The live audio of the conference call can also be accessed by telephone by dialing either (866) 999-CYTK (2985) ( United States and Canada ) or (706) 679-3078 (international) and typing in the passcode 2984784. css3 bootstrap theme 2 sidebarsWebNov 3, 2024 · Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised. ear blister treatmentWebCytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class … ear black removalWeb2 days ago · CYTOKINETICS, INC. : Trading strategies, financial analysis, commentaries and investment guidance for CYTOKINETICS, INC. Stock Nasdaq: Nasdaq css3 box showWebJul 19, 2024 · SOUTH SAN FRANCISCO, Calif., July 19, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced positive topline results … css3 background-sizeWebFeb 27, 2024 · Cytokinetics, Incorporated (NASDAQ:CYTK - Get Rating) has earned a consensus rating of "Moderate Buy" from the fifteen brokerages that are presently covering the stock, Marketbeat.com reports.One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and seven have given a buy … css3 bootstrapWebShare This: Share 2024 – Summer Analyst Internship – Financial Institutions Coverage (FIC) on Facebook Share 2024 – Summer Analyst Internship – Financial Institutions ... Financial Institutions Coverage (FIC) manages relationships with the bank’s largest institutional clients across key sectors: banks, hedge funds, asset managers ... css3 box-sizing value